* Co-first author.
**Co-second author.
§ Co-corresponding author.
1. Analysis of a miR-148a targetome in B cell central tolerance.
Ma F, Zhan Y, Bartolomé-Cabrero R, Ying W, Asano M, Huang Z, Xiao C§, Gonzalez-Martin A§.
Frontiers in Immunology. 2022 May 12;13:861655.
2. The chemokine receptor CCR5 links memory CD4 T cell metabolism to T cell antigen receptor nanoclustering.
Blanco R§, Gomez de Cedron M, Gamez-Reche L, Martin-Leal A, Gonzalez-Martin A, Lacalle RA, Ramirez de Molina A, Mañes S§.
Frontiers in Immunology. 2021 Dec 7;12:722320.
3. Regulation of adaptive tumor immunity by non-coding RNAs.
Papaioannou E*, Gonzalez-Molina MdP*, Prieto-Muñoz AM**, Gamez-Reche L**, Gonzalez-Martin A. Correspondence to: agonzalez@iib.uam.es
Cancers. 2021 Nov 12;13(22):5651.
4. Vaccine elicitation of HIV broadly neutralizing antibodies from engineered B cells.
Huang D, Tran JT, Olson A, Vollbrecht T, Tenuta M, Guryleva MV, Fuller RP, Schiffner T, Abadejos JR, Couvrette L, Blane TR, Saye K, Li W, Landais E, Gonzalez-Martin A, Schief W, Murrell B§, Burton DR§, Nemazee D§, Voss JE§.
Nature Communications. 2020 Nov 17;11(1):5850.
5. MicroRNA control of B cell tolerance, autoimmunity and cancer.
Xiao C, Nemazee D, Gonzalez-Martin A. Correspondence to: agonzalez@iib.uam.es
Seminars in Cancer Biology. 2020 Aug;64:102-107.
6. SOD3 induces a HIF-2α-dependent program in endothelial cells that provides a selective signal for tumor infiltration by T cells.
Carmona-Rodríguez L*, Martínez-Rey D*, Fernández-Aceñero MJ, Gonzalez-Martin A, Paz-Cabezas M, Rodríguez-Rodríguez N, Pérez-Villamil B, Sáez ME, Díaz-Rubio E, Mira E, Mañes S.
Journal for Immunotherapy of Cancer. 2020 Jun;8(1):e000432.
7. Reprograming the antigen specificity of B cells using genome-editing technologies.
Voss JE*§, Gonzalez-Martin A*§, Andrabi R*, Fuller RP, Murrell B, McCoy LE, Porter K, Huang D, Li W, Sok D, Le K, Briney BS, Chateau M, Rogers G, Hangartner L, Feeney AJ, Nemazee D, Cannon P, Burton D§.
Elife. 2019 Jan 17;8. pii: e42995.
8. Differential sensitivity of target genes to translational repression by miR-17-92.
Jin HY, Oda H, Chen P, Kang SG, Valentine E, Kefauver J, Liao L, Zhang Y, Gonzalez-Martin A, Shepherd J, Morgan GJ, Mondala TS, Schaffer L, Papp S, Yates Iii JR, Head SR, Han J, Williamson JR, Xiao C.
PLoS Genetics. 2017 Feb 27;13(2):e1006623.
9. Regulation of B cell development and tolerance by different members of the miR-17-92 family microRNAs.
Lai M*, Gonzalez-Martin A*, Cooper AB*, Oda H, Jin HY, Shepherd J, He L, Zhu J, Nemazee D§, Xiao C§.
Nature Communications. 2016 Aug 2;7:12207.
This article was recommended as of special relevance by Faculty of 1000 (F1000Prime).
10. A miR-155-Peli1-c-ReI pathway controls the generation and function of T follicular helper cells.
Liu WH, Kang SG, Huang Z, Wu CJ, Jin HY, Maine CJ, Shepherd J, Sabouri-Ghomi M, Gonzalez-Martin A, Xu S, Hoffmann A, Zheng Y, Lu LF, Xiao N, Fu G, Xiao C.
Journal of Experimental Medicine. 2016 Aug 1. pii: jem.20160204.
11. The microRNA-183-96-182 cluster promotes T helper 17 cell pathogenicity by negatively regulating transcription factor Foxo1 expression.
Ichiyama K, Gonzalez-Martin A, Kim BS, Jin HY, Jin W, Xu W, Sabouri-Ghomi M, Xu S, Zheng P, Xiao C§, Dong C§.
Immunity. 2016 Jun 21;44(6):1284-98.
12. The microRNA miR-148a functions as a critical regulator of B cell tolerance and autoimmunity.
Gonzalez-Martin A, Adams BD, Lai M, Shepherd J, Salvador-Bernaldez M, Salvador JM, Lu J, Nemazee D§, Xiao C§.
Nature Immunology. 2016 Apr;17(4):433-40.
This article was featured in News and Views, Nature Immunology. 2016 Apr;17(4):353-4.
Article recommended as of special relevance by Faculty of 1000 (F1000Prime).
13. Transfection of microRNA mimics should be used with caution.
Jin HY*, Gonzalez-Martin A*, Miletic AV, Lai M, Knight S, Sabouri-Ghomi M, Head SR, Macauley MS, Rickert RC, Xiao C.
Frontiers of Genetics. 2015 Dec 2;6:340.
14. A lovastatin-elicited genetic program inhibits M2 macrophage polarization and enhances T cell infiltration into spontaneous mouse mammary tumors.
Mira E, Carmona-Rodriguez L, Tardaguila M, Azcoitia I, Gonzalez-Martin A, Almonacid L, Casas J, Fabrias G, Mañes S.
Oncotarget. 2013 Dec;4(12):2288-301.
15. CCR5 in cancer immunotherapy: More than an "attractive" receptor for T cells.
Gonzalez-Martin A, Mira E, Mañes S.
Oncoimmunology. 2012 Jan 1;1(1):106-108.
16. CCR5 as a potential target in cancer therapy: inhibition or stimulation?
Gonzalez-Martin A, Mira E, Mañes S.
Anticancer Agents Medicinal Chemistry. 2012 Nov;12(9):1045-57.
17. Maximal T cell-mediated antitumor responses rely upon CCR5 expression in both CD4(+) and CD8(+) T cells.
Gonzalez-Martin A, Gomez L, Lustgarten J, Mira E§, Mañes S§.
Cancer Research. 2011 Aug 15;71(16):5455-66.
18. 1alpha,25-Dihydroxyvitamin D3 regulates the expression of Id1 and Id2 genes and the angiogenic phenotype of human colon carcinoma cells.
Fernandez-Garcia NI, Palmer HG, Garcia M, Gonzalez-Martin A, del Rio M, Barettino D, Volpert O, Muñoz A, Jimenez B.
Oncogene. 2005 Sep 29;24(43):6533-44.
19. Inhibition of xenografted human melanoma growth and prevention of metastasis development by dual antiangiogenic/antitumor activities of pigment epithelium-derived factor.
Garcia M, Fernandez-Garcia NI, Rivas V, Carretero M, Escamez MJ, Gonzalez-Martin A, Medrano EE, Volpert O, Jorcano JL, Jimenez B§, Larcher F§, Del Rio M§.
Cancer Research. 2004 Aug 15;64(16):5632-42.
20. Parent phenotype and age dependence, on rat glioma tumor rejection.
Gonzalez-Martin A, Muñoz-Espin D, Alonso AM, Izquierdo M.
Journal of Neuro-oncology. 2004 Oct;70(1):29-34.
B cell receptor (BCR) engineering in B cell lines and primary B cells.
Voss J*, Gonzalez-Martin A*, Andrabi R*, Huang D*, Burton D*. (* Equal contribution)
International patent, WO2019/028417, 7/2/2019. The Scripps Research Institute.
Use of the Extracellular Superoxide Dismutase (SOD-3) for the adjuvant immunotherapy of cancer.
Mañes S, Mira E, Gonzalez-Martin A, Tardaguila M.
Spain, P201031015. Issued November 2012.